Pages that link to "Q71340074"
Jump to navigation
Jump to search
The following pages link to In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors (Q71340074):
Displaying 50 items.
- Cytochrome P4502C9: an enzyme of major importance in human drug metabolism (Q24683497) (← links)
- Optimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolites (Q27027286) (← links)
- Pediatric Statin Administration: Navigating a Frontier with Limited Data (Q28068014) (← links)
- HMG-CoA reductase inhibitors and P-glycoprotein modulation (Q28360140) (← links)
- The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers (Q28373284) (← links)
- Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes (Q28547949) (← links)
- Fluvastatin: a review of its use in lipid disorders (Q33611948) (← links)
- Effects of the antifungal agents on oxidative drug metabolism: clinical relevance (Q33858325) (← links)
- Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure (Q33861870) (← links)
- HMG-CoA reductase inhibitors and myotoxicity (Q33956728) (← links)
- Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors (Q33959388) (← links)
- Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events (Q34147623) (← links)
- Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants (Q34163351) (← links)
- Clinical pharmacokinetics of fluvastatin (Q34257901) (← links)
- Drug interactions with irbesartan (Q34347254) (← links)
- Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? (Q34478635) (← links)
- Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers (Q34507491) (← links)
- Physicians' interpretation of "class effects": a need for thoughtful re-evaluation (Q34726091) (← links)
- Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin (Q34773911) (← links)
- Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin (Q34787395) (← links)
- Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. (Q34983265) (← links)
- Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression (Q35062493) (← links)
- Pharmacokinetic interactions with rifampicin : clinical relevance (Q35185727) (← links)
- Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management (Q35202958) (← links)
- Genetic variation, β-blockers, and perioperative myocardial infarction (Q35580952) (← links)
- Clinical implications of pharmacogenomics of statin treatment (Q36426816) (← links)
- Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans (Q36687277) (← links)
- Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program (Q36852416) (← links)
- Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa (Q37019758) (← links)
- Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children (Q38049379) (← links)
- Mechanism of Drug-Drug Interactions Between Warfarin and Statins. (Q38776313) (← links)
- Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences (Q41478162) (← links)
- Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations (Q41593016) (← links)
- Concomitant administration of simvastatin with ivabradine in contrast to metoprolol intensifies slowing of heart rate in normo- and hypercholesterolemic rats (Q41888327) (← links)
- Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy (Q42167855) (← links)
- Drug-drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats (Q42573118) (← links)
- Safety of the combination of intensive cholesterol-lowering therapy with oral anticoagulation medication in elderly patients with atrial fibrillation: a randomized, double-blind, placebo-controlled study (Q43298380) (← links)
- Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients (Q45224264) (← links)
- Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms (Q46796142) (← links)
- Synergistic effects of HMG-CoA reductase inhibitor and angiotensin II receptor blocker on load-induced heart failure. (Q53823579) (← links)
- Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. (Q53906841) (← links)
- Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. (Q53968585) (← links)
- Concomitant administration of different doses of simvastatin with ivabradine influence on PAI-1 and heart rate in normo- and hypercholesterolaemic rats. (Q55687041) (← links)
- Rhabdomyolysis due to interaction of simvastatin with mibefradil (Q56832784) (← links)
- Molecular Determinants of Substrate Affinity and Enzyme Activity of a Cytochrome P450 Variant (Q57044266) (← links)
- Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin (Q60486829) (← links)
- The impact of simvastatin on warfarin disposition and dose requirements (Q63241946) (← links)
- Combination of pravastatin and cyclosporin in transplant patients (Q73152456) (← links)
- Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60) (Q73712937) (← links)
- Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 (Q73924048) (← links)